Motus GI to Present at the Oppenheimer 28th Annual Healthcare Conference
Published: Mar 13, 2018
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that Mark Pomeranz, CEO, will present at the Oppenheimer 28th Annual Healthcare Conference in New York City on Tuesday, March 20, 2018 at 3:20 p.m. ET.
Mr. Pomeranz will provide a corporate update and discuss the Company's strategy for its flagship product, the Pure-Vu® System. The Pure-Vu System works with standard colonoscopes to help facilitate the cleaning of poorly prepped colons during the colonoscopy procedure, while preserving standard procedural workflow and techniques. Pure-Vu’s unique capability to cleanse the colon intra-procedurally may reduce the sole dependency on the pre-procedural preparation that many patients find difficult to tolerate, especially patients with medical issues and those that need a colonoscopy in an emergent situation. The Pure-Vu System received 510(k) clearance from the U.S. Food and Drug Administration and CE mark approval in Europe, and is currently being introduced on a pilot basis in the U.S.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company's website at www.motusgi.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended from time to time, under the caption "Risk Factors."
Source: Motus GI Holdings, Inc.